超越肠道:左甲状腺素吸收不良、药代动力学与给药途径
本文综述2023年以来关于难治性原发性甲减的文献,结合2例病例,区分真性吸收不良与假性吸收不良(不依从),并讨论快速吸收试验、液体制剂优势及皮下给药等替代途径。
要点
- 难治性甲减需区分真性吸收不良与假性吸收不良(不依从),监督下吸收试验有助鉴别。
- 快速吸收试验(2–3小时)是传统长时程方案的可行且经济的替代。
- 皮下左甲状腺素可用于胃肠吸收受损者,但尚无标准化吸收试验,需药代动力学评估。
核心结论
- 难治性原发性甲减的管理需先区分真性吸收不良与假性吸收不良,再个体化选择给药途径。
研究设计与样本
- 小型综述,检索PubMed自2023年以来的41篇相关文献,包括病例报告、药理学研究和临床研究,并附2例临床病例。
主要发现
- 病例1为先天性甲减年轻女性,监督下左甲状腺素吸收试验显示肠道吸收充分,后续支持假性吸收不良。
- 病例2为甲状腺乳头状癌合并终末期肾衰竭男性,吸收试验证实胃肠吸收受损,需肠外治疗,皮下左甲状腺素最终实现生化稳定。
- 近期研究验证了快速吸收方案(2–3小时),较传统长时程方案更可行且经济。
- 新兴文献提示胃肠、手术和药物因素可导致真性吸收不良,液体制剂在特定情境下具有优势。
- 皮下给药作为耐受性好、患者友好的肌注替代方案受到关注,但肠外T4的安全性和药代动力学验证仍必要。
关键数值与推荐
- 难治性原发性甲减定义为尽管口服左甲状腺素剂量超生理量,促甲状腺激素仍持续升高。
- 快速吸收试验方案时长为2–3小时。
- 目前尚无针对超说明书肌注或皮下给药的标准化吸收试验,药代动力学原理(尤其曲线下面积计算)可能有助于估计吸收准备情况。
临床怎么用
- 对难治性甲减患者,应先通过监督下吸收试验区分真性吸收不良与假性吸收不良。
- 假性吸收不良者需加强依从性管理;真性吸收不良者可考虑液体制剂或肠外给药。
- 皮下左甲状腺素可作为肌注的替代选择,但需注意缺乏标准化吸收试验,应结合药代动力学评估。
局限性
- 本文为小型综述,仅纳入41篇文献及2例病例,证据级别有限。
- 肠外T4的安全性和药代动力学尚未得到充分验证。
- 新型制剂仍在研发中,其疗效和安全性有待进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Refractory primary hypothyroidism is defined by persistently elevated thyroid-stimulating hormone despite supraphysiological oral levothyroxine dosing. The distinction between true malabsorption and pseudomalabsorption (nonadherence) is critical for management planning. In 2023, Quiroz-Aldave et al proposed a comprehensive framework for the evaluation and management of refractory primary hypothyroidism, while Liu et al provided an updated overview of both conventional and novel levothyroxine formulations. This mini-review synthesizes recent evidence published since 2023 and presents 2 illustrative cases managed within our clinical service. A PubMed search identified 41 relevant publications, including case reports, pharmacological studies, and clinical investigations. Case 1, a young woman with congenital hypothyroidism, demonstrated adequate intestinal absorption on a supervised levothyroxine absorption test, with subsequent findings supporting pseudomalabsorption. Recent studies have validated rapid absorption protocols (2-3 hours), offering feasible and cost-effective alternatives to conventional prolonged protocols. Case 2, a man with papillary thyroid carcinoma and end-stage renal failure, exhibited impaired gastrointestinal absorption confirmed by absorption testing. Management required escalation to parenteral therapy, with subcutaneous levothyroxine ultimately achieving biochemical stability. Importantly, no standardized absorption test exists for off-label intramuscular or subcutaneous administration; pharmacokinetic principles, particularly area under the curve calculations, may help estimate absorption readiness in these contexts. Emerging literature highlights gastrointestinal, surgical, and pharmacologic contributors to true malabsorption, as well as the superiority of liquid formulations in selected contexts. Subcutaneous administration is gaining interest as a tolerable, patient-friendly alternative to intramuscular dosing, although safety and pharmacokinetic validation of parenteral T4 remain necessary. Novel formulations under development may further optimize therapeutic options.
引用
- Law LS, Kuu NWX, Leong MHT, et al. Beyond the Gut: thyroxine malabsorption, pharmacokinetics, and delivery. J Clin Endocrinol Metab. 2026. PMID: 41572575. doi:10.1210/clinem/dgag024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。